

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1-66. (Cancelled)

67. (Currently Amended) A method for treating a subject having above normal platelet count comprising

administering to the subject in need of such treatment an MPL pathway inhibitory agent in an amount effective to reduce platelet count to at least a low normal level.

68. (New) The method of claim 67, wherein the platelet count is reduced to a below normal level.

69. (New) The method of claim 67, wherein platelet count is reduced by at least 50%.

70. (New) The method of claim 67, wherein platelet count is reduced to below 250×10^3 platelets per μl .

71. (New) The method of claim 67, wherein platelet count is reduced to below 200×10^3 platelets per μl .

72. (New) The method of claim 67, wherein platelet count is reduced to below 150×10^3 platelets per μl .

73. (New) The method of claim 67, wherein platelet count is reduced to below 100×10^3 platelets per μl .

74. (New) The method of claim 67, wherein the subject is a human.

75. (New) The method of claim 67, wherein the subject has an abnormally elevated risk of a thrombotic event.

76. (New) The method of claim 67, wherein the effective amount of the MPL pathway inhibitory agent is in the range of 0.001 mg/kg/day to 10 mg/kg/day.

77. (New) The method of claim 67, wherein the effective amount of the MPL pathway inhibitory agent is in the range of 0.001 mg/kg/day to 30 mg/kg/day.

78. (New) The method of claim 67, wherein the MPL pathway inhibitory agent is administered with an agent for treating vascular disorder or vascular complication.

79. (New) The method of claim 78, wherein the agent for treating vascular disorder or vascular complication is an anti-thrombotic agent.

80. (New) The method of claim 79, wherein the anti-thrombotic agent is selected from the group consisting of anti-coagulant agents, fibrinolytic agents and inhibitors of platelet function.

81. (New) The method of claim 80, wherein the inhibitors of platelet function are selected from the group consisting of aspirin, abciximab, clopidogrel and dipyridamole.

82. (New) The method of claim 80, wherein the anti-coagulant agents are selected from the group consisting of glycosaminoglycans and vitamin K antagonists.

83. (New) The method of claim 80, wherein the fibrinolytic agents are selected from the group consisting of plasminogen activators, plasmin and plasminogen.

84. (New) The method of claim 83, wherein the plasminogen activators are selected from the group consisting of tissue plasminogen activator (TPA), streptokinase and urokinase.

85. (New) The method of claim 67, wherein the MPL pathway inhibitory agent is administered by a parenteral route.

86. (New) The method of claim 67, wherein the MPL pathway inhibitory agent is administered by an enteral route.